Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), and End User (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Global Opportunity Analysis and Industry Forecast, 20182025
- Published Date: 2020-10-18
- Report ID: 3506
- Pages: 210
-
Format:
The early toxicity testing market accounted for $739 million in 2017, and is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.
The degree of threat posed by a chemical substance to the living organism is defined as toxicity. The branch of science that deals with measurement and further analysis of the adverse effects caused by these chemical substances on the body of an organism is called as toxicology. Toxicity testing of chemical substances is performed to select a potential drug candidate for development of newer molecules. Early toxicity is essential as it is the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Therefore, early toxicity testing is carried out at preclinical stages of a drug development process. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. There are different techniques such as in vivo, in vitro, and in silico that are employed for testing drug to monitor early toxicity associated with them. Different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others are performed using these techniques.
Major factors that drive the market growth are surge in the R&D activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in in vitro techniques, rise in adoption of in vitro models in early toxicity testing industry across the globe, and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the global early toxicity testing market on the basis of technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.
On the basis of end user, the market is segmented into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Region wise, the market is studied across different regions such as North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Technique
In Vivo
In Vitro
o In Vitro Toxicity Testing Market by Assays
Enzyme Toxicity Assays
Bacterial Toxicity Assays
Cell-Based ELISA and Western Blots
Tissue Culture Assays
Receptor Binding Assays
Other Assays
o In Vitro Toxicity Testing Market by Toxicity Endpoints
Dermal Toxicity
Systemic Toxicity
Carcinogenicity
Ocular Toxicity
Skin Sensitization and Irritation
Genotoxicity
Neurotoxicity
Organ Toxicity
Other Toxicity Endpoints
o In Silico
By End User
Pharmaceuticals Industry
Food Industry
Chemicals Industry
Cosmetics Industry
Other Industries
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Rest of Europe
Asia-Pacific
o India
o China
o Japan
o Australia
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Agilent Technologies, Inc.
General Electric Company (GE Healthcare)
Danaher Corporation (Beckman Coulter, Inc.)
Evotec AG (Cyprotex)
Bioanalytical Systems, Inc.
Bruker Corporation
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
Myriad Genetics, Inc. (Myriad RBM.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Randox Toxicology
Geneva Laboratories, Inc.
Advanced Chemistry Development (ACD/Labs)
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Government regulations
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Surge in R&D activities in healthcare
3.6.1.2. Rise in adoption of in vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraint
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunity
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact analysis
CHAPTER 4: EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.4. In vitro early toxicity testing market, by assay
4.3.4.1. Enzyme toxicity assays
4.3.4.1.1. Market size and forecast
4.3.4.2. Bacterial toxicity assays
4.3.4.2.1. Market size and forecast
4.3.4.3. Cell-based ELISA and western blots
4.3.4.3.1. Market size and forecast
4.3.4.4. Tissue culture assays
4.3.4.4.1. Market size and forecast
4.3.4.5. Receptor binding assays
4.3.4.5.1. Market size and forecast
4.3.4.6. Others
4.3.4.6.1. Market size and forecast
4.3.5. In vitro early toxicity testing market, by toxicity end-point
4.3.5.1. Dermal toxicity
4.3.5.1.1. Market size and forecast
4.3.5.2. Systemic toxicity
4.3.5.2.1. Market size and forecast
4.3.5.3. Carcinogenicity
4.3.5.3.1. Market size and forecast
4.3.5.4. Ocular toxicity
4.3.5.4.1. Market size and forecast
4.3.5.5. Skin sensitization and irritation
4.3.5.5.1. Market size and forecast
4.3.5.6. Genotoxicity
4.3.5.6.1. Market size and forecast
4.3.5.7. Neurotoxicity
4.3.5.7.1. Market size and forecast
4.3.5.8. Organ toxicity
4.3.5.8.1. Market size and forecast
4.3.5.9. Others
4.3.5.9.1. Market size and forecast
4.4. In silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical industry
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Food industry
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Chemicals industry
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Cosmetic industry
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: EARLY TOXICITY TESTING MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. early toxicity testing market, by technique type
6.2.2.1.2. U.S. early toxicity testing market, by end user
6.2.2.2. Canada
6.2.2.2.1. Canada early toxicity testing market, by technique type
6.2.2.2.2. Canada early toxicity testing market, by end user
6.2.2.3. Mexico
6.2.2.3.1. Mexico early toxicity testing market, by technique type
6.2.2.3.2. Mexico early toxicity testing market, by end user
6.2.3. Market size and forecast, by technique type
6.2.4. Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany early toxicity testing market, by technique type
6.3.2.1.2. Germany early toxicity testing market, by end user
6.3.2.2. France
6.3.2.2.1. France early toxicity testing market, by technique type
6.3.2.2.2. France early toxicity testing market, by end user
6.3.2.3. UK
6.3.2.3.1. UK early toxicity testing market, by technique type
6.3.2.3.2. UK early toxicity testing market, by end user
6.3.2.4. Rest of Europe
6.3.2.4.1. Rest of Europe early toxicity testing market, by technique type
6.3.2.4.2. Rest of Europe early toxicity testing market, by end user
6.3.3. Market size and forecast, by technique type
6.3.4. Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan early toxicity testing market, by technique type
6.4.2.1.2. Japan early toxicity testing market, by end user
6.4.2.2. China
6.4.2.2.1. China early toxicity testing market, by technique type
6.4.2.2.2. China early toxicity testing market, by end user
6.4.2.3. Australia
6.4.2.3.1. Australia early toxicity testing market, by technique type
6.4.2.3.2. Australia early toxicity testing market, by end user
6.4.2.4. India
6.4.2.4.1. India early toxicity testing market, by technique type
6.4.2.4.2. India early toxicity testing market, by end user
6.4.2.5. Rest of Asia-Pacific
6.4.2.5.1. Rest of Asia-Pacific early toxicity testing market, by technique type
6.4.2.5.2. Rest of Asia-Pacific early toxicity testing market, by end user
6.4.3. Market size and forecast, by technique type
6.4.4. Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil early toxicity testing market, by technique type
6.5.2.1.2. Brazil early toxicity testing market, by end user
6.5.2.2. South Africa
6.5.2.2.1. South Africa early toxicity testing market, by technique type
6.5.2.2.2. South Africa early toxicity testing market, by end user
6.5.2.3. Rest of LAMEA
6.5.2.3.1. xx early toxicity testing market, by technique type
6.5.2.3.2. rest of LAMEA early toxicity testing market, by end user
6.5.3. Market size and forecast, by technique type
6.5.4. Market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES
7.1. AGILENT TECHNOLOGIES, INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product type Portfolio
7.1.5. Business performance
7.2. BIOANALYTICAL SYSTEMS, INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. BRUKER CORPORATION
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. DANAHER CORPORATION (BECKMAN COULTER, INC.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product type portfolio
7.4.5. Business performance
7.5. EVOTEC AG (CYPROTEX)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. ENZO BIOCHEM, INC. (ENZO CLINICAL LABS, INC.)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. GENERAL ELECTRIC COMPANY (GE HEALTHCARE)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. MYRIAD GENETICS, INC. (MYRIAD RBM.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Product Portfolio
7.8.4. Business performance
7.9. PERKINELMER INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. THERMO FISHER SCIENTIFIC, INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
